{"id":"NCT00798161","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design","officialTitle":"A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Free Combination of BI 1356 2.5 mg + Metformin 500 mg, or of BI 1356 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg Twice Daily), and BI 1356 (5.0 mg Once Daily) Over 24 Weeks in Drug Naive or Previously Treated (4 Weeks Wash-out and 2 Weeks Placebo run-in) Type 2 Diabetic Patients With Insufficient Glycaemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-05","completion":null,"firstPosted":"2008-11-25","resultsPosted":"2011-08-04","lastUpdate":"2014-01-28"},"enrollment":857,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"BI 1356","otherNames":[]},{"type":"DRUG","name":"BI 1356 + metformin","otherNames":[]},{"type":"DRUG","name":"Bi 1356 + metformin","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"metformin","otherNames":[]},{"type":"DRUG","name":"matching placebo","otherNames":[]}],"arms":[{"label":"BI 1356 + metformin","type":"EXPERIMENTAL"},{"label":"matching placebo","type":"PLACEBO_COMPARATOR"},{"label":"BI 1356+ Metformin","type":"EXPERIMENTAL"},{"label":"Metformin","type":"ACTIVE_COMPARATOR"},{"label":"metformin","type":"ACTIVE_COMPARATOR"},{"label":"BI 1356","type":"EXPERIMENTAL"}],"summary":"The objective of the randomised part of the study is to investigate the efficacy and safety of BI 1356 plus metformin compared to BI 1356 or metformin alone given for 24 weeks to drug naive or previously treated (4 weeks wash-out, 2 weeks placebo run-in) type 2 diabetic patients with insufficient glycaemic control. For the open-label part of the study the objective is to estimate the efficacy and safety of BI 1356 and metformin in type 2 diabetic patients with very poor glycaemic control for 24 weeks","primaryOutcome":{"measure":"HbA1c Change From Baseline at Week 24","timeFrame":"Baseline and week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.13,"sd":0.11},{"arm":"M500BID","deltaMin":-0.64,"sd":0.08},{"arm":"M1000BID","deltaMin":-1.07,"sd":0.08},{"arm":"Lina5","deltaMin":-0.45,"sd":0.08},{"arm":"L2.5+M500BID","deltaMin":-1.22,"sd":0.08},{"arm":"L2.5+M1000BID","deltaMin":-1.59,"sd":0.08}],"pValues":[{"comp":"OG001 vs OG004","p":"<0.0001"},{"comp":"OG002 vs OG005","p":"<0.0001"},{"comp":"OG003 vs OG004","p":"<0.0001"},{"comp":"OG003 vs OG005","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":138,"countries":["Canada","Croatia","Estonia","France","Germany","India","Lithuania","Mexico","Netherlands","Romania","Russia","Sweden","Tunisia","Ukraine"]},"refs":{"pmids":["32328953"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":72},"commonTop":["Hyperglycaemia","Diarrhoea","Nasopharyngitis","Hypertension","Glomerular filtration rate decreased"]}}